About Vial
Vial is a Healthcare company based in San Francisco (United States) founded in 2020 by Simon Burns and Andrew Brackin. Healthcare data capture, clinical trials, and CRO services are provided. Vial has raised $67 million across 1 funding round from investors including General Catalyst, BoxGroup and Byers Capital. The company has 65 employees. Its chief executive, as recorded, is Simon Burns. Its website vial.com draws about 16 thousand monthly visits. Its focus areas include Biopharma Outsourcing, CRO, Clinical Development and Functional Services. Its competitors include Javara Research, Alcanza Clinical Research and The START Center for Cancer Research; 2 of its 3 listed competitors have raised funding.
Company details
Vial was founded in 2020 and is headquartered in San Francisco, United States. Operations center on healthcare data capture, clinical trial management, and CRO services within the biotech sector. Clinical trials are overseen for sponsors through integrated technology platforms and teams experienced in clinical operations and technology. Full-service support is extended to streamline trial processes across various therapeutic areas.
- Annual Revenue$110.71 K (USD)23as on Dec 31, 2022
- Net Profit$50.01 K (USD)-27as on Dec 31, 2022
- Total Equity Funding$67M (USD)
in 1 rounds
- Latest Funding Round$67M (USD), Series B
Dec 2022
- InvestorsGeneral Catalyst
& 2 more
- Employee Count65
Funding Insights of Vial
Vial has successfully raised a total of $67M through 1 strategic funding round. The most recent funding activity was a Series B round of $67 million completed in December 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $67M
- Total Rounds 1
- Last Round Series B — $67M
- First Round $67M
(Dec 2022)
- Investors Count 3
All 1 funding rounds of Vial with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2022 | $67M | Series B | – | General Catalyst |
3 investors in total: 3 institutional.
Investors in Vial
Vial has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include General Catalyst, BoxGroup and Byers Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment and transformation services for entrepreneurs in technology and finance sectors. | generalcatalyst.com | |||
Investing in early-stage tech companies and ideas. | boxgroup.com | |||
Byers Capital is engaged in direct investments in technology and biotechnology. | byerscap.com |
Investor details for Vial
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Vial
34 people are tracked at Vial (14 in leadership, 20 in team); the tracked headcount is 65.
| Name | Role | Group |
|---|---|---|
Simon Burns | Co-Founder & CEO | Leadership |
Andrew Brackin | Co-Founder | Leadership |
Max James | Chief Business Officer | Leadership |
Eric Pao | Strategic Finance Director | Leadership |
Ira Saini | Director of Product | Leadership |
Sarah Wise | Director of Scientific Operations | Leadership |
Samir Meghji | Chief Financial Officer | Leadership |
Catie Neel | Vice President, People | Leadership |
John Sheperdson | Director Of Business Development | Leadership |
Preeti Sareen | Head of Strategy | Leadership |
Joshua Pascoe | Chief Operations Officer | Leadership |
Eric P. | Strategic Finance Director | Leadership |
Carlos Naranjo | Vice President, Business Development | Leadership |
Will Sulpizio | Director of Finance | Leadership |
Alexandra “Sasha” Thompson | Regulatory & Compliance Manager | Team |
Ife Desamours | Strategy Associate | Team |
Owen Allen | Marketing & People Operations Manager | Team |
Aleina Lee | Controller | Team |
Wendy Oraeki | Clinical Research Associate II | Team |
Ana Peredo | Senior Strategy Associate | Team |
14 more people are available in the full profile.
Complete people profiles for Vial
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Vial
2 dated milestones of Vial across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Vial is founded.
- Funding First funding round of $67.0M.
Competitors of Vial
Vial has 3 listed competitors in our database, 2 of them funded. They include Javara Research, Alcanza Clinical Research and The START Center for Cancer Research.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| javararesearch.com | 2018 | Winston-salem, United States | $44.98M | Clinical trials for pharmaceuticals are conducted across therapeutic areas. | ||
| alcanzaclinical.com | 2021 | Methuen, United States | Clinical research site network focused on accelerating the development of new therapies by reducing barriers to participation | |||
| startresearch.com | 2007 | San Antonio, United States | $13.84M | Early-phase oncology clinical trials and research services are provided. |
Detailed competitors of Vial
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Vial
The website of Vial (vial.com) receives about 16.4K visits a month and ranks #1,847,851 among all websites worldwide, #2,529 in Biotechnology and Pharmaceuticals.
- Monthly visits16.4K
▲ 29.9% vs previous month
- Unique visitors5.3K
per month
- Global rank#1,847,851
among all websites
- Category rank#2,529
Health · Biotechnology and Pharmaceuticals
- Bounce rate36%
- Pages per visit1.9
- Average visit22 sec
- DevicesDesktop 29% · Mobile 71%
Websites whose visitors overlap most with Vial. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| astellasgenetherapies.com | 100% | 1K | View details | ||
| corvuspharma.com | 99% | 13.6K | #3,366,661 | View details | |
| nurixtx.com | 98% | 11.5K | #2,207,206 | View details | |
| mbcbiolabs.com | 97% | #2,013,343 | View details | ||
| eurekatherapeutics.com | 95% | 1.7K | #7,320,910 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 35 similar websites and full traffic analytics for Vial
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 35 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Vial (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vial
Complete news archive for Vial
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vial
Vial was founded in 2020 and raised its 1st funding round 2 years after it was founded.
Vial is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Simon Burns is the CEO of Vial, as recorded in our data. They have also founded this company.
Vial is a funded company, having raised a total of $67M across 1 funding round to date. The company's 1st funding round was a Series B of $67M, raised on Dec 2022.
Vial has 65 employees.
Annual revenue of Vial is $110.71K as on Dec 31, 2022.
Vial was founded in 2020 and is headquartered in San Francisco, United States. Operations center on healthcare data capture, clinical trial management, and CRO services within the biotech sector. Clinical trials are overseen for sponsors through integrated technology platforms and teams experienced in clinical operations and technology. Full-service support is extended to streamline trial processes across various therapeutic areas.
Vial's top competitors include Javara Research, The START Center for Cancer Research and Alcanza Clinical Research.
Vial has 3 investors. Key investors include General Catalyst, BoxGroup, and Byers Capital.